Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease.
OBJECTIVE
To investigate if a central cholinesterase inhibitor will reduce falling frequency in subjects with Parkinson disease (PD) with advanced postural instability.


BACKGROUND
Falling due to postural instability is a significant problem in advancing PD, and is minimally impacted by dopaminergic therapy. Anticholinergic medications increase falling in the elderly. Further, CNS cholinergic neuron loss occurs in PD. We hypothesized that acetylcholine augmentation may reduce frequent falling in subjects with PD.


METHODS
We enrolled 23 subjects with PD who reported falling or nearly falling more than 2 times per week. In a randomized, placebo-controlled, crossover design, subjects were given 6 weeks of donepezil or placebo with a 3-week washout between phases. The primary outcomes were daily falls and near falls reported on postcards. Secondary outcomes included scores on the Activities of Balance Confidence Scale, Berg Balance Scale, Clinical Global Impression of Change, Folstein Mini-Mental State Examination, and the motor section of the Unified Parkinson's Disease Rating Scale.


RESULTS
Fall frequency per day on placebo was 0.25 ± 0.08 (SEM) compared with 0.13 ± 0.03 on donepezil (p < 0.05). The frequency of near falls was not significantly different between phases. The secondary outcomes did not differ; however, there was a trend to improvement on the subject-completed Global Impression of Change scale.


CONCLUSIONS
Subjects with PD fell approximately half as often during the 6 weeks on donepezil than on placebo. Larger trials of cholinergic augmentation are warranted in subjects with PD with frequent falls.


METHODS
This study provides Class II evidence that donepezil (maximum 10 mg per day) significantly reduced the number of falls in patients with PD (0.13 falls/day, SEM = 0.03) than when taking placebo (0.25 falls/day, SEM = 0.08, p = 0.049).
Chung
Kathryn A
KA
Department of Neurology, Oregon Health & Science University, Portland, OR, USA. chungka@ohsu.edu
Lobb
Brenna M
BM
Nutt
John G
JG
Horak
Fay B
FB
D000368:Aged; D002800:Cholinesterase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D018592:Cross-Over Studies; D004185:Disability Evaluation; D000077265:Donepezil; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007189:Indans / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000150:complications* / Q000188:drug therapy; D010880:Piperidines / Q000494:pharmacology / Q000627:therapeutic use*; D004856:Postural Balance / Q000187:drug effects; D012678:Sensation Disorders / Q000188:drug therapy* / Q000209:etiology*; D012720:Severity of Illness Index; D018709:Statistics, Nonparametric
D002800:Cholinesterase Inhibitors; D007189:Indans; D010880:Piperidines; D000077265:Donepezil
Synapse. 2002 Jul;45(1):1-9
12112408
Neuroscience. 2002;113(3):493-507
12150770
Age Ageing. 2001 Jan;30(1):47-52
11322672
J Neurophysiol. 1996 Jun;75(6):2380-96
8793751
J Comp Neurol. 1993 Feb 15;328(3):364-76
8440786
J Neurol Neurosurg Psychiatry. 2006 Mar;77(3):322-6
16484639
Proc Natl Acad Sci U S A. 1987 Aug;84(16):5976-80
3475716
Ann Neurol. 1983 Mar;13(3):243-8
6847136
Brain Res Rev. 2006 Aug;51(2):145-60
16530842
Gait Posture. 2002 Aug;16(1):1-14
12127181
J Neurol. 2001 Nov;248(11):950-8
11757958
Int Psychogeriatr. 2002 Sep;14(3):307-10
12475091
Mov Disord. 2003 May;18(5):496-502
12722162
J Neurol Neurosurg Psychiatry. 2002 Jun;72(6):721-5
12023412
Arch Intern Med. 1991 Apr;151(4):754-6
2012459
Psychopharmacology (Berl). 2003 Apr;167(1):28-36
12618916
J Psychiatr Res. 1975 Nov;12(3):189-98
1202204
Brain. 2007 Jun;130(Pt 6):1596-607
17251240
J Neurosci Nurs. 2000 Aug;32(4):222-8
10994536
Exp Brain Res. 1991;85(3):475-81
1915707
Parkinsonism Relat Disord. 2008 Nov;14(7):553-7
18329941
J Am Geriatr Soc. 2002 Oct;50(10):1629-37
12366615
N Engl J Med. 2004 Dec 9;351(24):2509-18
15590953
J Gerontol A Biol Sci Med Sci. 1995 Jan;50A(1):M28-34
7814786
Neurology. 2009 Nov 17;73(20):1670-6
19917989
Prog Neurobiol. 1995 Sep;47(1):1-29
8570851
J Comp Neurol. 1994 Jun 8;344(2):210-31
8077458
Ann N Y Acad Sci. 1992 May 22;656:519-36
1318013
Can J Public Health. 1992 Jul-Aug;83 Suppl 2:S7-11
1468055
Neuroscience. 2008 Apr 22;153(1):72-83
18339485
Neuropsychologia. 2002;40(12):1948-55
12207992
Synapse. 2003 Apr;48(1):39-44
12557271
Acta Neuropathol. 1984;64(1):43-52
6089493
J Neural Transm (Vienna). 2006 Nov;113(11):1787-90
16758132
BMC Geriatr. 2009 Jul 23;9:30
19627577
J Neurol. 1999 Sep;246(9):783-8
10525975
J Am Geriatr Soc. 2003 Sep;51(9):1213-8
12919232
N Engl J Med. 1998 Sep 24;339(13):875-82
9744971